Sol-Gel Technologies Begins Phase 3 Study for SGT-610, a Potential Groundbreaking Treatment for Gorlin Syndrome
NESS ZIONA, Israel, Nov. 30, 2023 - Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a renowned dermatology company specializing in innovative therapies for severe skin conditions, has recently commenced Phase 3 testing for SGT-610, a promising new topical hedgehog inhibitor. The study aims to evaluate the gel’s effectiveness in preventing the development of basal cell carcinoma (BCC) lesions in patients suffering from Gorlin syndrome, a hereditary condition characterized by a high risk of skin cancer.
SGT-610, otherwise known as patidegib gel, 2%, has shown significant potential in combating Gorlin syndrome without the adverse effects associated with oral hedgehog inhibitors. Sol-Gel acquired the rights to patidegib from PellePharm, and it currently represents the sole therapy under development aimed at preventing new BCC lesions in Gorlin syndrome patients.
Gorlin syndrome, also referred to as nevoid basal cell carcinoma syndrome (NBCCS), is a rare genetic disorder that affects approximately 1 in 30,000 individuals worldwide. It is primarily characterized by a predisposition to the development of multiple BCCs throughout the body, including the face, trunk, and extremities. Such individuals often require ongoing treatment to manage these skin lesions, which can be physically and emotionally distressing. By focusing on prevention, Sol-Gel’s SGT-610 has the potential to revolutionize the treatment landscape for Gorlin syndrome patients.
The Phase 3 study will involve an extensive evaluation of SGT-610’s safety and efficacy in a large population of Gorlin syndrome patients. This trial will provide crucial insights into the gel’s ability to inhibit the growth of new BCC lesions, leading to improved patient outcomes and quality of life. Sol-Gel’s approach to dermatology revolves around leveraging innovative technologies and developing pioneering treatments. With two approved large-category dermatology products, TWYNEO and EPSOLAY, the company has already established itself as a leader in the field.
According to Dr. Alon Seri-Levy, CEO of Sol-Gel Technologies, This Phase 3 study represents a significant milestone in our commitment to provide game-changing solutions for patients with severe skin conditions. We are excited about the potential of SGT-610 in preventing the development of new BCC lesions and are hopeful that this therapy will revolutionize the management of Gorlin syndrome. Our primary focus continues to be on improving patient outcomes and enhancing their quality of life.
Gorlin syndrome patients, who often require frequent surgical or topical interventions to address their BCC lesions, stand to benefit greatly from the development of SGT-610. With its improved safety profile and localized application, this innovative gel has the potential to effectively halt the progression of BCC lesions, reducing the need for invasive treatments and associated complications.
Sol-Gel’s commitment to dermatology excellence, coupled with its ground-breaking products and pioneering research, has gained worldwide recognition. By advancing to Phase 3 testing for SGT-610, the company reaffirms its dedication to providing innovative, patient-centric solutions for severe skin conditions. With the first patient already screened for the study, the potential breakthrough treatment for Gorlin syndrome represents a promising step forward in dermatological advancements.
Comments